Quick Facts

• Overactive Bladder: Used to address the collection of symptoms associated with overactive bladder (OAB).
• Urinary Urgency: Helps to manage the sudden, compelling need to pass urine that is difficult to postpone.
• Urinary Frequency: Indicated for reducing the need to urinate more often than usual.
• Urge Incontinence: May help in addressing involuntary leakage of urine associated with a sudden urge to urinate.

---

Solifenacin Sandoz is a medication authorized for use in adults experiencing symptoms of an overactive bladder (OAB). The primary purpose of this treatment is to help manage disruptive symptoms that impact daily life.

This agent is indicated for the resolution of three key symptoms related to OAB. First, it is used to manage urinary urgency, which is characterized by a compelling, sudden need to urinate. Second, the treatment addresses urinary frequency, which involves needing to pass urine more often than is typical. Third, it may help in addressing urge urinary incontinence, which is the involuntary loss of urine associated with the urgent feeling of needing to go.

The use of this medication has demonstrated a link to positive patient outcomes in clinical settings, including the potential for increased functional bladder capacity. For more comprehensive information on the indications and usage, consult the prescribing information.

Who Can and Cannot Use Solifenacin Sandoz?

Solifenacin Sandoz is officially authorized for use in adults (18 years and older). Its eligibility profile is strictly defined by regulatory authorities based on pre-existing conditions and specific physiological states.

Contraindicated Populations

Use of this medicine is strictly prohibited in patients diagnosed with:

• Urinary retention or gastric retention.
• Uncontrolled narrow-angle glaucoma.
• Severe hepatic impairment (Child-Pugh Class C).
• Myasthenia gravis or severe gastrointestinal conditions.
• Known hypersensitivity to solifenacin succinate or any excipients.

---

Age and Condition-Based Restrictions

Population Group	Regulatory Status
Children & Adolescents (<18)	Not Established; use is generally not recommended.
Severe Renal Impairment	Conditional Use; maximum daily dose is restricted to 5 mg.
Moderate Hepatic Impairment	Conditional Use; maximum daily dose is restricted to 5 mg.
Pregnancy/Lactation	Restricted Use; generally not recommended.

For populations with bladder outflow obstruction or conditions that increase the risk of QT prolongation, use requires specific caution as detailed in regulatory documents.

Interactions with other medicines and products

Solifenacin Sandoz’s interaction profile is defined by its metabolic clearance pathway and its primary pharmacological activity. The medicine is a substrate of the CYP3A4 enzyme, which is the basis for several official pharmacokinetic interactions.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Interacting Substances	Outcome and Restriction
Metabolic (CYP3A4)	Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)	These increase Solifenacin exposure (AUC increased approximately three-fold with Ketoconazole 400 mg/day). Co-administration is contraindicated in patients with severe renal or moderate hepatic impairment.
Pharmacodynamic	Other Anticholinergic Medicines	Potential for more pronounced therapeutic and undesirable effects due to additive activity.
Pharmacodynamic	GI Motility Stimulants (e.g., Metoclopramide)	Solifenacin can reduce the effect of these drugs due to antagonistic activity.

Required Separations and Other Substances

When discontinuing Solifenacin and commencing other anticholinergic therapy, an interval of approximately one week should be allowed between treatments. The medicine’s absorption is not affected by food intake, allowing administration with or without meals. However, regulatory documents note that drinking alcohol may increase the risk of side effects such as drowsiness. Furthermore, the official profile notes a risk of additive effects when Solifenacin is used with medicinal products known to prolong the QT interval, and cautions against use with CYP3A4-affecting herbal products like St. John's Wort.

Targeting the M3 Receptor to Dampen Cholinergic Signaling

Solifenacin Sandoz functions as a competitive antagonist, engaging primarily with the M3 muscarinic receptors on the surface of the detrusor muscle. By binding to these sites, the molecule prevents the neurotransmitter acetylcholine (ACh) from activating the receptor, thereby interrupting the efferent nerve signal.

---

Inhibiting Detrusor Muscle Contractility

The molecular blockade of the M3 receptor inhibits the subsequent intracellular signaling cascade that involves the mobilization of calcium ions (Ca^2+), which are essential for smooth muscle contraction. This mechanistic action leads to the relaxation and decreased excitability of the detrusor muscle, leading to a reduction in the frequency and amplitude of uninhibited detrusor muscle contractions.

---

Increasing Bladder Volume Accommodation

The resultant physiological effect of detrusor muscle relaxation is a decrease in overall muscle tone and an increase in the tissue's compliance. This modulation of smooth muscle tone alters bladder function toward increased volume accommodation and functional capacity, directly linking the drug's mechanism to an altered physiological state.

---

Scope of Peripheral Anticholinergic Action

The underlying anticholinergic mechanism is functionally present wherever M3 receptors are located on peripheral smooth muscle and glandular tissue. The non-organ-specific nature of this binding is an inherent aspect of the molecule's mechanism, defining its range of engagement across multiple organ systems.

Official Administration Guidelines: Solifenacin Sandoz

Solifenacin Sandoz tablets must be taken orally and are dosed once daily.

Administration Details

• Route and Preparation: Tablets must be swallowed whole with a liquid, such as water. Do not crush, chew, or break the tablets. The dose can be taken with or without food.
• Adult Dosing: The standard starting oral dose is 5 mg once daily. If well-tolerated, the dose may be increased to a maximum of 10 mg once daily.
• Special Population Dosing: The daily dose must not exceed 5 mg in adults who have severe renal impairment (creatinine clearance leq 30 mL/min), moderate hepatic impairment (Child-Pugh B), or are concurrently taking potent CYP3A4 inhibitors (e.g., ketoconazole).
• Missed Dose: If a tablet dose is missed, skip the missed dose and take the next scheduled dose at the usual time the following day. Do not take two doses in the same day to compensate for a missed dose.

Pediatric Administration (Oral Suspension)

For pediatric patients 2 years of age and older, a weight-based oral suspension formulation is used. The dose is taken once daily. The bottle should be shaken well before each dose, and the liquid should be measured with a marked measuring device. It is recommended to follow the dose with a liquid (water or milk) and avoid taking it simultaneously with food or other drinks to prevent a bitter taste. If a dose is missed by more than 12 hours, that dose should be skipped.

Research evidence / Overview of Studies for Solifenacin Sandoz

1. Evidence for Use in Overactive Bladder (OAB) Symptoms

The primary evidence was evaluated in numerous Randomized Controlled Trials (RCTs) investigating solifenacin succinate. These short-term studies, which lasted around 12 weeks, were conducted during periods of increased symptom activity to explore how symptoms change over time when compared against an inactive substance, known as a placebo. Research explored the compound in adults who were experiencing OAB symptoms, such as the sudden, compelling need to pass urine (urgency) and needing to urinate much more often than usual (frequency).

Studies monitored outcomes related to functional imbalance by measuring changes in bladder diary variables. The research highlights changes measured during the study period, and evidence contributes to understanding symptom patterns related to these daily variables.

2. Research on Neurogenic Detrusor Overactivity (NDO)

Research examined Solifenacin succinate in conditions characterized by functional limitations caused by nerve damage, known as Neurogenic Detrusor Overactivity (NDO). The research monitored outcomes related to specific populations, such as those with bladder issues resulting from a Spinal Cord Injury (SCI) or Multiple Sclerosis (MS).

These studies focused on measuring specialized functional outcomes in addition to daily symptom changes. Researchers examined temporary physiological imbalance by monitoring urodynamic measures, which include parameters like the bladder's maximum storage capacity. Research for NDO is limited compared to the primary OAB indication.

3. Long-Term Studies and Follow-up Durations

Research examined follow-up over defined time intervals, with the short-term placebo-controlled trials typically concluding at 12 weeks. To gather observations beyond this period, researchers used open-label extension studies and real-world observational studies. These longer-duration settings provided insight into short-term changes that may be sustained over an intermediate period, with some patients observed for up to a year. However, long-term effects are not fully established, and follow-up durations were limited in many controlled research scenarios.

4. Summary of Evidence Gaps and Areas for Future Research

Evidence is limited regarding the long-term changes, as controlled trials were mostly short-term. Data for certain groups remain insufficient, especially those with coexisting medical conditions, which are common in conditions characterized by functional limitations. Subgroup findings concerning those with the most intense symptoms may be uncertain due to the design of the original trials. Research continues to explore symptom patterns over many years.

Key Studies & References

1. TRANSPARENCY COMMITTEE OPINION 7 October 2009 VESICARE 5 mg, coated tablet (Regulatory Indication Context)

Common questions about Solifenacin Sandoz (FAQ)

Q: How quickly should Solifenacin Sandoz start to work?

A: After taking the medicine, the active substance reaches its peak levels in the body within 3 to 8 hours. However, based on clinical data, the official product information indicates that the maximum therapeutic effect of the medicine is typically determined after 4 weeks of treatment, at the earliest.

Q: What is the difference between Solifenacin Sandoz and the brand name Vesicare?

A: Solifenacin Sandoz contains the active ingredient solifenacin succinate. Products like Solifenacin Sandoz are generic versions of the original brand name formulation, which is Vesicare. This means they contain the same active medicine and are used to treat the same conditions.

Q: If I miss a dose, what is the usual guidance for what to do?

A: Regulatory documents advise that if a tablet dose is missed, it should be skipped entirely. The guidance describes taking the next scheduled dose at the usual time the following day. It is specified that two doses should not be taken in the same day to make up for a missed dose.

Q: Can Solifenacin Sandoz affect kidney function over time?

A: Official post-marketing safety data have rarely reported the occurrence of kidney impairment. It is stated that specific dosing restrictions are mandated for patients who have pre-existing severe kidney impairment.

Q: What is the typical timeframe before noticing the full effect of the medicine?

A: The official documentation indicates that the maximum benefit of the medicine is generally observed after 4 weeks of treatment. This timeframe is based on clinical trial data gathered on the effectiveness of the drug.

Q: Are there any known interactions with herbal supplements like St. John's Wort?

A: Official prescribing information includes cautions regarding the use of this medicine with herbal products that affect the CYP3A4 enzyme system. One example is St. John’s Wort, as using it may change the concentration of solifenacin in the bloodstream.

Q: What information exists about Solifenacin Sandoz use in breastfeeding mothers?

A: Official regulatory documents state that it is not known whether the medicine passes into human milk. Based on animal studies showing excretion into milk, official information indicates that use of this medicine is generally restricted during the period of breastfeeding.

Q: Can I take Solifenacin Sandoz if I am already taking medication for depression or anxiety?

A: Solifenacin Sandoz is an anticholinergic medicine. Regulatory information cautions that combining it with other medicines that also have anticholinergic properties—which may include some medications for depression or anxiety—can potentially increase the risk of anticholinergic side effects.

Q: How does Solifenacin Sandoz get eliminated from the body?

A: The medicine is processed extensively in the liver, primarily through an enzyme system known as CYP3A4. Approximately 70% of the active substance and its components are eliminated from the body through the urine, with the remainder eliminated through the feces.

Q: Is Solifenacin Sandoz the same type of medicine as Oxybutynin?

A: Yes, Solifenacin Sandoz and Oxybutynin both belong to the same class of drugs, known as antimuscarinic agents or anticholinergics. They function by blocking muscarinic receptors to help relax the bladder muscle and are used to manage overactive bladder symptoms.

Q: What are the most common reasons someone would stop taking Solifenacin Sandoz?

A: Data from clinical trials suggest that the most common reasons for discontinuation in clinical studies are related to anticholinergic side effects. These include issues like dry mouth, constipation, and blurred vision.

Q: Why do doctors prescribe Solifenacin Sandoz instead of other options?

A: Official documents highlight that this medicine is approved for once-daily dosing and is a selective antimuscarinic agent used to help relax the bladder muscle. The choice between this medicine and other options is based on a healthcare professional's assessment, which is not detailed in the drug's official regulatory documentation.

Q: What if I feel dizzy after starting Solifenacin Sandoz?

A: Dizziness is listed as a possible side effect of this medicine. Regulatory documents advise monitoring for central nervous system effects, particularly when starting treatment or increasing the dose. Official warnings recommend not to drive or operate heavy machinery until the medicine's effect on the person is known.

Q: What are the main risks associated with Solifenacin Sandoz for people with heart issues?

A: The main risk noted in regulatory documents is the potential for an effect on the heart's rhythm called QT prolongation. Caution is officially advised for people who have a known risk factor for QT prolongation or who are taking other medications that may affect heart rhythm.

Q: Is Solifenacin Sandoz used for any purpose other than bladder control?

A: The medicine is officially indicated for treating Overactive Bladder symptoms in adults. Additionally, the oral suspension formulation is approved for the treatment of Neurogenic Detrusor Overactivity (NDO) in certain pediatric patients aged 2 years and older.

Q: Can the medicine be taken if I have difficulty swallowing pills?

A: The tablet formulation must be swallowed whole. However, an oral suspension (liquid) formulation is available and approved for use in the pediatric population (2 years and older). The availability of this formulation may be an option for certain patients, which can be discussed with a healthcare professional.

Q: Is it possible to develop a tolerance to Solifenacin Sandoz?

A: Clinical trial data from long-term extension studies, gathered over a 12-month period, showed that improvements in efficacy were sustained over time. This suggests that the medicine continues to be effective for many patients throughout this observed period.

Q: If I am taking a narcotic painkiller, can I still take Solifenacin Sandoz?

A: Official warnings state that Solifenacin Sandoz is associated with central nervous system side effects such as drowsiness and dizziness. Combining it with other CNS depressant medicines, which can include narcotic painkillers, may increase the risk of these effects.

Q: Is a metallic taste in the mouth a possible side effect of Solifenacin Sandoz?

A: Yes, an altered sense of taste, technically called dysgeusia, has been classified as an uncommon side effect in official regulatory documents.

Q: Can Solifenacin Sandoz be used to treat bedwetting?

A: Official indications for use in the pediatric population are limited to the treatment of Neurogenic Detrusor Overactivity (NDO). The medicine is not specifically indicated or approved for the general treatment of bedwetting, or nocturnal enuresis.

Q: What are the research findings on patient satisfaction with Solifenacin Sandoz?

A: Research published on long-term open-label extension studies has reported high percentages of patient satisfaction. These findings relate to both the medicine’s tolerability and its continued effectiveness over a 12-month period.

This medication must be stored according to official regulatory requirements to maintain its stability and to ensure safety. The tablets must be kept in their original container, tightly closed, and stored at controlled room temperature, typically between 15 C to 30 C (59 F to 86 F), or below 25 C.

It is mandatory to store Solifenacin Sandoz out of the sight and reach of children.

For disposal, the best method is to use a drug take-back program or event. If these are unavailable, do not flush the tablets down the toilet. The official guidance for household disposal is to mix the medicine (without crushing) with an undesirable substance, such as used coffee grounds or cat litter, place the mixture in a sealed container, and dispose of it in the trash.